|
|
Article: WARNER-LAMBERT'S ACCUPRIL CLEARED FOR TREATMENT OF HEART FAILURE
- Article from:
- PR Newswire
- Article date:
- November 3, 1993
CopyrightCOPYRIGHT 1993 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MORRIS PLAINS, N.J., Nov. 3 /PRNewswire/ -- Warner-Lambert Company (NYSE: WLA) today said the U.S. Food and Drug Administration has granted expanded labeling for Accupril (quinapril hydrochloride tablets) as adjunctive therapy for the treatment of congestive heart failure (CHF). The drug, currently marketed in the U.S. for the treatment of hypertension, was unanimously recommended for clearance by an FDA advisory committee in February.
An ACE (angiotensin-converting enzyme) inhibitor developed by the company's Parke-Davis division, Accupril is available for use in more than 40 countries, mostly for the treatment of both hypertension and CHF. It received marketing clearance ...